MYDECINE ANNOUNCES FILING OF Q3 FINANCIAL
STATEMENTS
Vancouver, British Columbia, 21
November 2024 - Mydecine Innovations Group Inc. (the
"Company")
(CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) is pleased to
confirm that the Company has filed on SEDAR+
its interim Q3 financial statements, accompanying management
discussion and analysis and related CEO and CFO certifications for
the nine months ended 30 September
2024 (the "Quarterly
Filings").
The Quarterly Filings can be obtained on the Company's SEDAR+
profile at
www.sedarplus.ca.
The
Directors of Mydecine take responsibility for this
announcement.
This
announcement contains inside information for the purposes of
Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms
part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the Company's obligations under Article 17 of MAR.
On behalf
of the Board of Directors,
MYDECINE
INNOVATIONS GROUP INC.
Joshua Bartch
Chief
Executive Officer
contact@mydecineinc.com
AQSE
Corporate Advisor
Novum
Securities Limited Tel:
+44 (0)207 399 9400
David Coffman/ George
Duxberry
About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a biotechnology company developing
the next generation of innovative medications and therapies to
address mental health disorders such as nicotine addiction and
posttraumatic stress disorder (PTSD). The core strategy blends
advanced technology with an elaborate infrastructure for drug
discovery and development. Mydecine's dedicated multinational team
constantly develops new paths for breakthrough treatment solutions
in areas with considerable unmet needs. By collaborating with some
of the world's leading specialists, the Company aspires to
responsibly speed up the development of breakthrough medications to
provide patients with safer and more effective treatment solutions.
At the same time, Mydecine's approach focuses on the next
generation of psychedelic medicine by creating innovative compounds
with unmatched therapeutic potential through its clinical trial
efforts with worldclass scientific and regulatory
expertise.
Learn more at: https://www.mydecine.com/ and follow the company on
Twitter, LinkedIn, YouTube, and Instagram.
Forward-looking Information Statement
This news release may contain certain "forward-looking
statements" and "forward-looking information" within the meaning of
applicable Canadian and United
States securities laws. When used in this news release, the
words "anticipate", "believe", "estimate", "expect", "target,
"plan", "forecast", "may", "schedule" and other similar words or
expressions identify forward-looking statements or information.
These forward-looking statements or information may relate to the
anticipated timing for the filing of the Annual Filings, and other
factors or information. Such statements represent the Company's
current views with respect to future events and are necessarily
based upon a number of assumptions and estimates that, while
considered reasonable by the Company, are inherently subject to
significant business, economic, competitive, political and social
risks, contingencies and uncertainties. Many factors, both known
and unknown, could cause results, performance or achievements to be
materially different from the results, performance or achievements
that are or may be expressed or implied by such forward-looking
statements. The Company does not intend, and does not assume any
obligation, to update these forward-looking statements or
information to reflect changes in assumptions or changes in
circumstances or any other events affections such statements and
information other than as required by applicable laws, rules and
regulations
NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED
OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE.
